词条 | Ezetimibe/atorvastatin |
释义 |
| type = combo | component1 = Ezetimibe | class1 = Hypolipidemic agent | component2 = Atorvastatin | class2 = Statin | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | CAS_number = | ATCvet = | ATC_prefix = C10 | ATC_suffix = BA05 | DrugBank = | PubChem = 16007392 | KEGG = D10385 }}Ezetimibe/atorvastatin (brand name Liptruzet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013 by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet.[1] Liptruzet has also been approved to reduce elevated total cholesterol and elevated LDL in patients diagnosed with homozygous familial hypercholesterolemia as an adjunctive treatment to other hyperlipidemia treatments. [2] Some cardiologists opposed the approval, because the combination reduced LDL cholesterol in a clinical trial, but it did not reduce heart disease. A clinical trial studying the endpoints of heart attacks, strokes and heart-related deaths is scheduled to conclude in 2014.[3] Liptruzet was withdrawn from sale by its manufacturer in June 2015 but not for reasons of safety or effectiveness.[4] Mechanism of ActionThis combination drug works to reduce cholesterol levels through two different pathways. The ezetimibe component of the medication works by inhibiting cholesterol absorption from food while the atorvastatin component inhibits intrinsic cholesterol production in the liver. [5] Safe Use
Commonly Reported Adverse Reactions
See also
References1. ^{{cite news | title = FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol | url = http://www.businesswire.com/news/home/20130503006107/en/ADDING%C2%A0MULTIMEDIA-FDA-Approves-Merck%E2%80%99s-LIPTRUZET%E2%84%A2-ezetimibe-atorvastatin | publisher = Business Wire | date = May 6, 2013 | accessdate = May 6, 2013}} {{Lipid modifying agents}}{{Merck&Co}}{{DEFAULTSORT:Ezetimibe atorvastatin}}{{cardiovascular-drug-stub}}2. ^ 2. "Liptruzet." CenterWatch. Web. 28 Oct. 2014. 3. ^[https://www.nytimes.com/2013/05/04/business/fda-approves-mercks-combination-drug-to-reduce-cholesterol.html Drug to Cut Cholesterol Is Approved by the F.D.A.] By KATIE THOMAS, New York Times, May 3, 2013 4. ^ [https://www.federalregister.gov/documents/2015/11/20/2015-29639/determination-that-liptruzet-ezetimibe-and-atorvastatin-tablets-10-milligrams10-milligrams-10. Determination That LIPTRUZET (Ezetimibe and Atorvastatin) Tablets, 10 Milligrams/10 Milligrams, 10 Milligrams/20 Milligrams, 10 Milligrams/40 Milligrams, and 10 Milligrams/80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness] Federal Register: Notice by the Food and Drug Administration on 11/20/2015. 5. ^Liptruzet [package insert]. Whitehouse Station, NJ: Merck & Co.; 2013 6. ^Merck Sharp & Dohme Corp. Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Oct 28]. Available from: http://clinicaltrials.gov/show/NCT00418834 NLM Identifier: NCT00418834 7. ^ Merck Sharp & Dohme Corp. Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Oct 28]. Available from: http://clinicaltrials.gov/show/NCT00418834 NLM Identifier: NCT00418834 8. ^Merck Sharp & Dohme Corp. Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 Oct 28]. Available from: http://clinicaltrials.gov/show/NCT00418834 NLM Identifier: NCT00418834 3 : Hypolipidemic agents|Combination drugs|Merck |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。